Načítá se...
Does TMB impact the effectiveness of TKIs in EGFR-mutant NSCLC?
Patients with EGFR-mutant NSCLC achieve variable benefit from targeted therapy, and biomarkers to predict degree of benefit are not in clinical use. EGFR-mutant cancers with high tumor mutational burden demonstrate poorer outcomes on EGFR targeted therapy. Investigation into the mechanisms underlyin...
Uloženo v:
| Vydáno v: | Clin Cancer Res |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6359945/ https://ncbi.nlm.nih.gov/pubmed/30190372 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-18-2368 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|